NCT05732831 2026-04-21Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT07283731 2026-04-17Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaM.D. Anderson Cancer CenterPhase 2 Recruiting20 enrolled
NCT02298959 2026-04-13Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerNational Cancer Institute (NCI)Phase 1 Active not recruiting59 enrolled